Back to Search Start Over

Explainable 18F-FDG PET/CT radiomics model for predicting EGFR mutation status in lung adenocarcinoma: a two-center study.

Authors :
Zuo, Yan
Liu, Qiufang
Li, Nan
Li, Panli
Fang, Yichong
Bian, Linjie
Zhang, Jianping
Song, Shaoli
Source :
Journal of Cancer Research & Clinical Oncology; Oct2024, Vol. 150 Issue 10, p1-12, 12p
Publication Year :
2024

Abstract

Purpose: To establish an explainable <superscript>18</superscript>F-FDG PET/CT-derived prediction model to identify EGFR mutation status and subtypes (EGFR wild, EGFR-E19, and EGFR-E21) in lung adenocarcinoma (LUAD). Methods: Baseline <superscript>18</superscript>F-FDG PET/CT images of 478 patients with LUAD from 2 hospitals were collected. Data from hospital A (n = 390) was randomly split into a training group (n = 312) and an internal test group (n = 78), with data from hospital B (n = 88) utilized for external test. Further, a total of 4,760 handcrafted radiomics features (HRFs) were extracted from PET/CT scans. Candidates for the prediction model were constructed by cross-combinations of 11 feature selection methods and 7 classifiers. The optimal model was determined by combining the results of cross-center data validation and model visualization (Yellowbrick). The predictive performance was assessed via receiver operating characteristic curve, confusion matrix and classification report. Four explainable artificial intelligence technologies were used for optimal model interpretation. Results: Sex and SUV<subscript>max</subscript> were selected as clinical risk factors, which were then combined with 8 robust PET/CT HRFs to establish the models. The optimal performance was obtained by combining a light gradient boosting machine classifier with random forest feature selection method achieving an optimal performance with a macro-average AUC of 0.75 in the internal test group and 0.81 in the external test group. Conclusion: The explainable EGFR mutation status prediction model have certain clinical practicability and good generalization performance, which may help in the timely selection of treatment options and prognosis prediction in patients with LUAD. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
01715216
Volume :
150
Issue :
10
Database :
Complementary Index
Journal :
Journal of Cancer Research & Clinical Oncology
Publication Type :
Academic Journal
Accession number :
180437888
Full Text :
https://doi.org/10.1007/s00432-024-05998-7